tiprankstipranks
InMed Pharmaceuticals Showcases Growth and Drug Advancements
Company Announcements

InMed Pharmaceuticals Showcases Growth and Drug Advancements

Story Highlights

InMed Pharmaceuticals (INM) has released an update.

Pick the best stocks and maximize your portfolio:

InMed Pharmaceuticals Inc. has reported a modest revenue increase and promising developments in their Alzheimer’s and dry AMD drug programs. With a revenue of $4.6M, marking an 11% increase from the previous fiscal year, the company is progressing with its INM-901 program for Alzheimer’s and INM-089 for dry AMD, suggesting potential future growth in its pharmaceutical pipeline.

For further insights into INM stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskInMed Pharmaceuticals Explores CBN for Skin Disease Treatment
TipRanks Canadian Auto-Generated NewsdeskInMed’s Study Highlights Cannabinol’s Potential in Skincare
TipRanks Auto-Generated NewsdeskInMed Pharmaceuticals Reports Improved Quarterly Earnings
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App